Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma
Status:
Completed
Trial end date:
2017-09-20
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well dovitinib works in treating patients with recurrent or
progressive glioblastoma. Dovitinib may stop the growth of tumor cells by blocking some of
the enzymes needed for cell growth